Physician profile
Mohammad Fattal
NPI 1114194156
$5,379.89
in general payments reported to CMS, 2019-2025
34 companies · $5.69 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $1,003 · 2021: $1,522 · 2022: $1,852 · 2023: $45.32 · 2025: $5.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $51.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $51.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $590.85 | 2019-2022 | |
| Lilly USA, LLC | $572.73 | 2019-2022 | |
| Astellas Pharma US INC | $523.49 | 2019-2023 | Myrbetriq |
| Abbvie INC. | $505.43 | 2021-2023 | |
| Amarin Pharma, INC. | $473.76 | 2019-2022 | |
| Pfizer INC. | $422.99 | 2019-2022 | |
| Novo Nordisk INC | $410.54 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $283.06 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.14 | 2019-2022 | |
| Glaxosmithkline, LLC. | $198.55 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $169.10 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $156.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $114.42 | 2022 | |
| Abbott Laboratories | $77.12 | 2021-2025 | Freestyle Libre 3 |
| Aprecia Pharmaceuticals, LLC | $74.24 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $71.03 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $61.13 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.08 | 2022 | |
| Merck Sharp & Dohme LLC | $54.14 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.44 | 2020 | |
| Biogen, INC. | $37.76 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.03 | 2022 | |
| Nestle Healthcare Nutrition INC. | $31.56 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $30.39 | 2020-2021 | |
| Edwards Lifesciences Corporation | $27.73 | 2020 | |
| Sun Pharmaceutical Industries INC. | $21.83 | 2021 | |
| Mdd US Operations, LLC | $17.87 | 2019 | |
| Eisai INC. | $16.24 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.12 | 2022 | |
| Avanir Pharmaceuticals, INC. | $13.82 | 2020 | |
| Lucid Diagnostics INC. | $13.45 | 2022 | |
| Mylan Specialty L.P. | $12.92 | 2023 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $12.61 | 2019 | |
| Upsher-Smith Laboratories LLC | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Fattal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.